4.4 Review

Combating Hepatitis C Virus by Targeting MicroRNA-122 Using Locked Nucleic Acids

Journal

CURRENT GENE THERAPY
Volume 12, Issue 4, Pages 301-306

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156652312802083558

Keywords

Clinical trials; gene targeting; hepatitis C virus; locked nucleic acids; microRNA-mRNA interactions; viral gene expression

Funding

  1. NIH [AI069000, AI47365, 5T32 AI007328]
  2. American Liver Foundation (ALF)
  3. National CIHR Research Training Program in Hepatitis C (NCRTP-HepC)

Ask authors/readers for more resources

MicroRNAs have been predicted to regulate the stability and translation of many target mRNAs that are involved in modulating disease outcome. Thus, valuable strategies to enhance or to diminish the function of microRNAs are needed to manipulate microRNA-mediated target gene expression. Recently, it has become apparent that one class of antisense oligonucleotides, locked nucleic acids, can be used to sequester microRNAs in the liver of a variety of animals including humans, opening the possibility of applying locked nucleic acid-mediated gene therapy. This review summarizes the success of sequestration of liver-specific microRNA miR-122 by antisense locked nucleic acids and their use in combating hepatitis C virus in clinical trials.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available